Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events
- 1 April 2010
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 32 (4), 667-677
- https://doi.org/10.1016/j.clinthera.2010.04.009
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Impact of Fixed-Dose Combination Drugs on Adherence to Prescription MedicationsJournal of General Internal Medicine, 2008
- OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelinesOsteoarthritis and Cartilage, 2008
- The Tell-Tale Heart: Population-Based Surveillance Reveals an Association of Rofecoxib and Celecoxib with Myocardial InfarctionPLOS ONE, 2007
- American College of Gastroenterology Guideline on the Management of Helicobacter pylori InfectionAmerican Journal of Gastroenterology, 2007
- Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus ReportGut, 2007
- Summing the risk of NSAID therapyThe Lancet, 2007
- Inappropriate Prevention of NSAID-Induced Gastrointestinal Events Among Long-Term Users in the ElderlyDrugs & Aging, 2007
- Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trialsBMJ, 2006
- The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitorAlimentary Pharmacology & Therapeutics, 2006
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005